The incidence of early-onset colorectal cancer (EO-CRC; diagnosed before age 50 years) is increasing worldwide. Although current data indicate that EO-CRC may be biologically distinct from average-onset CRC (AO-CRC; diagnosed at age ≥50 years), molecular differences remain poorly defined. To address this knowledge gap,...
Caroline B. M. Porter, Shane P. Murphy, Jules Cazaubiel et al.· Nature Medicine· 0 citations
PURPOSE
Circulating tumor DNA (ctDNA) could be a powerful prognostic biomarker for patients with locally advanced esophageal cancer but higher sensitivity is needed. An ultrasensitive test could enable improved treatment decision-making by accurately identifying patients with residual disease.
EXPERIMENTAL DESIGN
331...
J. Rhoades, Anuj K. Patel, K. Xiong et al.· Clinical Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is refractory to most therapies, including immunotherapies, for which reinvigoration of CD8 T cells through immune checkpoint blockade is insufficient to induce long-term, durable remissions. Direct KRAS inhibitors (KRASi) have shown clinical promise, although acquired resistance...
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cell· 0 citations
This approach may serve as a first-stage, low-cost clinical stratification tool to identify high-risk individuals before more resource-intensive downstream screening such as pancreas-directed imaging as well as promising generalizability to an independent healthcare system.
Ji-Fan Gao, Mina Stanikic, Eshna Lahr et al.· Cancer Research· 0 citations
Recent studies have identified a high prevalence of low grade pancreatic intraepithelial neoplasia (PanIN) in the pancreata of healthy adults. This study aimed to characterize the transcriptomic landscape of human PanINs at single cell resolution, with the goal of identifying hallmarks of initiation and progressi...
C. Nguyen, Anders W. Ohman, Winston R. Becker et al.· Cancer Research· 0 citations
IL-21-elicited CD4 T cells exert anti-tumor activity in mice, and potentially in humans, which can convert transient responses to KRAS inhibition into durable remissions in pancreatic cancer.
Li Qiang, Megan T. Hoffman, Jung-Ho Chun et al.· Cancer Research· 0 citations
A large-scale international programme—the Human Cancer Models Initiative—is presented, which involved the generation of a resource of 665 next-generation models from 2,780 donors with 25 cancer types and integrated tumour–model whole genome, exome, methylome and transcriptome analyses.
Dina Elharouni, Mushriq Al-Jazrawe, Seongmin Choi et al.· Nature· 7 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.